You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.
To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.
Urothelial Cancer
Publication Date: May 23, 2021
Last Updated: March 14, 2022
Diagnostic tests and biomarkers for urothelial cancer immunotherapy
Currently, the evidence does not support routine use of biomarkers to guide BCG therapy in NMIBC. Cystoscopy (with biopsy/transurethral resection (TUR) of bladder tumor as needed), urine cytology, and periodic upper tract imaging should be used to detect recurrence.
()
1317211
Non-muscle-invasive bladder cancer
BCG is recommended for all eligible patients with high-risk NMIBC (including cases with CIS or papillary tumors).